Free shipping on all orders over $ 500

LAQ824

Cat. No. M1747

All AbMole products are for research use only, cannot be used for human consumption.

LAQ824 Structure
Synonym:

NVP-LAQ824

Size Price Availability Quantity
5mg USD 150  USD150 In stock
10mg USD 225  USD225 In stock
50mg USD 600  USD600 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

LAQ824 (NVP-LAQ824) is a potent novel histone deacetylase (HDAC) inhibitor with an IC50 of 0.032 μM. NVP-LAQ824 also inhibited patient MM cell growth in a dose- and time-dependent manner. NVP-LAQ824-induced apoptotic signaling includes up-regulation of p21, caspase cascade activation, and poly (adenosine diphosphate [ADP]) ribose (PARP) cleavage.

Protocol (for reference only)
Cell Experiment
Cell lines HCT116, H1299, PC-3, DU145 and MDA435 cells
Preparation method Monolayer Growth Inhibition Assay. Cell proliferation was measured using an adaptation of published procedures (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfonyl)-2H-tetrazolium assay) as described previously (29) . The CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay was performed according to the manufacturer’s protocol. The average background value (treatment with medium alone) was subtracted from each experimental well; triplicate values were averaged for each compound dilution. The following formulas were used to calculate the percentage of growth: The “% Growth” was plotted against compound concentration and used to calculate the IC50 using the linear regression techniques between data points to predict the concentration of compounds at 50% inhibition.
Concentrations 0~10 μM
Incubation time 72 hr
Animal Experiment
Animal models HCT116 cells tumor-bearing mice
Formulation dissolved in DMSO to create a stock solution, which was further diluted just before dosing with D5W to a final DMSO concentration of 10%.
Dosages once daily, 5 days/week, for a total of 15 doses.
Administration i.v. injection into the tail vein
Chemical Information
Molecular Weight 379.459
Formula C22H25N3O3
CAS Number 404951-53-7
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Beloueche-Babari M et al. Cancer Res. Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancers.

[2] Wang H et al. J Immunol. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10.

[3] Schwarz K et al. Leuk Res. The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells.

[4] Cho YS et al. J Med Chem. Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824).

[5] Vo DD et al. Cancer Res. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.

[6] Ellis L et al. Blood. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.

[7] Atadja P, et al. Cancer Res. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.

Related HDAC Products
CM-444

CM-444 is an inhibitor for HDAC and DNA methyltransferases (DNMT) with IC50 values of 6 nM-0.6 μM and 1.8-2.3 μM, respectively. CM-444 is an inducer for the differentiation of acute myeloid leukemia cells. CM-444 exhibits anti-leukemic activity and improves the survival rate in mouse models.

CM-1758

CM-1758 is a histone deacetylase (HDAC) inhibitor. CM-1758 inhibits tumor growth in vivo. CM-1758 induces acetylation of non-histone proteins in acute myeloid leukemia cells.

T-518 

T-518 is an orally active, selective, and blood-brain barrier permeable HDAC6 inhibitor with an IC50 value of 36 nM for human HDAC6.

SE-7552 

SE-7552, a 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate HDAC6 inhibitor with an IC50 of 33 nM.

BRD9757 

BRD9757 is a potent, capless and selective HDAC6 inhibitor with an IC50 of 30 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: LAQ824, NVP-LAQ824 supplier, HDAC, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.